Review



target specific fak sirna  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 91
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology target specific fak sirna
    Inhibition of <t>FAK</t> Signaling Induces Cell Blebbing and a Caspase-Dependent Anoikis (A) Quantification of Annexin V/7-AAD positive cells by flow cytometry in hESCs treated for 24 hr with the indicated concentrations of PF562271, DMSO, or untreated. ∗ p < 0.05 relative to DMSO. (B) Caspase activity in hESCs treated for 5 hr with the indicated concentration of FAK inhibitors. ∗ p < 0.05 relative to DMSO. (C) Caspase activity in hESCs treated for 5 hr with the indicated concentration of AKT inhibitors. ∗ p < 0.05 relative to DMSO. (D) Cleaved caspase-3 expression in hESCs treated with DMSO, FAKi only, or with 50 μM ZVAD-FMK for 24 hr. ∗ p < 0.05 relative to DMSO. (E) Phase images of hESCs treated for 24 hr with DMSO, FAKi only, or with Z-VAD-FMK. Inset shows blebbing in a single cell (a) or groups of cells (b). Scale bar, 100 μm. (F) Dot plots of Annexin V/7-AAD-positive cells in hESCs treated for 24 hr with DMSO, FAKi only, or with Z-VAD-FMK. (G) Immunoblot for FAK and GAPDH in hESCs nucleofected with mock control, control GFP vector (ctl vector) plus FAK <t>siRNA</t> (siFAK), or siFAK for 48 hr. Bottom: protein knockdown efficiency. ∗ p < 0.05. (H) Top: phase images of hESCs after knockdown with β2-microglobulin siRNA (siB2M) control or siFAK for 66 hr. Bottom: hESCs after treatment with 10 μg/mL of IgG isotype or MAB13 antibody for 24 hr. Scale bars, 100 μm (top) and 50 μm (bottom). (I) Quantification of Annexin V-positive hESCs after knockdown with siB2M or siFAK (66 hr). ∗∗ p < 0.03. (J) Quantification of Annexin V/7-AAD-positive hESCs after knockdown with siB2M or siFAK (66 hr). (K) Quantification of Annexin V/7-AAD-positive hESCs treated with IgG or MAB13 antibody (24 hr). ∗ p < 0.05. Data represent mean + SEM (n = 3 experiments). See also <xref ref-type=Figure S2 . " width="250" height="auto" />
    Target Specific Fak Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 91/100, based on 56 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/target specific fak sirna/product/Santa Cruz Biotechnology
    Average 91 stars, based on 56 article reviews
    target specific fak sirna - by Bioz Stars, 2026-02
    91/100 stars

    Images

    1) Product Images from "Integrin-Associated Focal Adhesion Kinase Protects Human Embryonic Stem Cells from Apoptosis, Detachment, and Differentiation"

    Article Title: Integrin-Associated Focal Adhesion Kinase Protects Human Embryonic Stem Cells from Apoptosis, Detachment, and Differentiation

    Journal: Stem Cell Reports

    doi: 10.1016/j.stemcr.2016.07.006

    Inhibition of FAK Signaling Induces Cell Blebbing and a Caspase-Dependent Anoikis (A) Quantification of Annexin V/7-AAD positive cells by flow cytometry in hESCs treated for 24 hr with the indicated concentrations of PF562271, DMSO, or untreated. ∗ p < 0.05 relative to DMSO. (B) Caspase activity in hESCs treated for 5 hr with the indicated concentration of FAK inhibitors. ∗ p < 0.05 relative to DMSO. (C) Caspase activity in hESCs treated for 5 hr with the indicated concentration of AKT inhibitors. ∗ p < 0.05 relative to DMSO. (D) Cleaved caspase-3 expression in hESCs treated with DMSO, FAKi only, or with 50 μM ZVAD-FMK for 24 hr. ∗ p < 0.05 relative to DMSO. (E) Phase images of hESCs treated for 24 hr with DMSO, FAKi only, or with Z-VAD-FMK. Inset shows blebbing in a single cell (a) or groups of cells (b). Scale bar, 100 μm. (F) Dot plots of Annexin V/7-AAD-positive cells in hESCs treated for 24 hr with DMSO, FAKi only, or with Z-VAD-FMK. (G) Immunoblot for FAK and GAPDH in hESCs nucleofected with mock control, control GFP vector (ctl vector) plus FAK siRNA (siFAK), or siFAK for 48 hr. Bottom: protein knockdown efficiency. ∗ p < 0.05. (H) Top: phase images of hESCs after knockdown with β2-microglobulin siRNA (siB2M) control or siFAK for 66 hr. Bottom: hESCs after treatment with 10 μg/mL of IgG isotype or MAB13 antibody for 24 hr. Scale bars, 100 μm (top) and 50 μm (bottom). (I) Quantification of Annexin V-positive hESCs after knockdown with siB2M or siFAK (66 hr). ∗∗ p < 0.03. (J) Quantification of Annexin V/7-AAD-positive hESCs after knockdown with siB2M or siFAK (66 hr). (K) Quantification of Annexin V/7-AAD-positive hESCs treated with IgG or MAB13 antibody (24 hr). ∗ p < 0.05. Data represent mean + SEM (n = 3 experiments). See also <xref ref-type=Figure S2 . " title="Inhibition of FAK Signaling Induces Cell Blebbing and a Caspase-Dependent Anoikis ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: Inhibition of FAK Signaling Induces Cell Blebbing and a Caspase-Dependent Anoikis (A) Quantification of Annexin V/7-AAD positive cells by flow cytometry in hESCs treated for 24 hr with the indicated concentrations of PF562271, DMSO, or untreated. ∗ p < 0.05 relative to DMSO. (B) Caspase activity in hESCs treated for 5 hr with the indicated concentration of FAK inhibitors. ∗ p < 0.05 relative to DMSO. (C) Caspase activity in hESCs treated for 5 hr with the indicated concentration of AKT inhibitors. ∗ p < 0.05 relative to DMSO. (D) Cleaved caspase-3 expression in hESCs treated with DMSO, FAKi only, or with 50 μM ZVAD-FMK for 24 hr. ∗ p < 0.05 relative to DMSO. (E) Phase images of hESCs treated for 24 hr with DMSO, FAKi only, or with Z-VAD-FMK. Inset shows blebbing in a single cell (a) or groups of cells (b). Scale bar, 100 μm. (F) Dot plots of Annexin V/7-AAD-positive cells in hESCs treated for 24 hr with DMSO, FAKi only, or with Z-VAD-FMK. (G) Immunoblot for FAK and GAPDH in hESCs nucleofected with mock control, control GFP vector (ctl vector) plus FAK siRNA (siFAK), or siFAK for 48 hr. Bottom: protein knockdown efficiency. ∗ p < 0.05. (H) Top: phase images of hESCs after knockdown with β2-microglobulin siRNA (siB2M) control or siFAK for 66 hr. Bottom: hESCs after treatment with 10 μg/mL of IgG isotype or MAB13 antibody for 24 hr. Scale bars, 100 μm (top) and 50 μm (bottom). (I) Quantification of Annexin V-positive hESCs after knockdown with siB2M or siFAK (66 hr). ∗∗ p < 0.03. (J) Quantification of Annexin V/7-AAD-positive hESCs after knockdown with siB2M or siFAK (66 hr). (K) Quantification of Annexin V/7-AAD-positive hESCs treated with IgG or MAB13 antibody (24 hr). ∗ p < 0.05. Data represent mean + SEM (n = 3 experiments). See also Figure S2 .

    Techniques Used: Inhibition, Flow Cytometry, Activity Assay, Concentration Assay, Expressing, Western Blot, Control, Plasmid Preparation, Knockdown



    Similar Products

    target specific fak sirna  (Santa Cruz Biotechnology)
    91
    Santa Cruz Biotechnology target specific fak sirna
    Inhibition of <t>FAK</t> Signaling Induces Cell Blebbing and a Caspase-Dependent Anoikis (A) Quantification of Annexin V/7-AAD positive cells by flow cytometry in hESCs treated for 24 hr with the indicated concentrations of PF562271, DMSO, or untreated. ∗ p < 0.05 relative to DMSO. (B) Caspase activity in hESCs treated for 5 hr with the indicated concentration of FAK inhibitors. ∗ p < 0.05 relative to DMSO. (C) Caspase activity in hESCs treated for 5 hr with the indicated concentration of AKT inhibitors. ∗ p < 0.05 relative to DMSO. (D) Cleaved caspase-3 expression in hESCs treated with DMSO, FAKi only, or with 50 μM ZVAD-FMK for 24 hr. ∗ p < 0.05 relative to DMSO. (E) Phase images of hESCs treated for 24 hr with DMSO, FAKi only, or with Z-VAD-FMK. Inset shows blebbing in a single cell (a) or groups of cells (b). Scale bar, 100 μm. (F) Dot plots of Annexin V/7-AAD-positive cells in hESCs treated for 24 hr with DMSO, FAKi only, or with Z-VAD-FMK. (G) Immunoblot for FAK and GAPDH in hESCs nucleofected with mock control, control GFP vector (ctl vector) plus FAK <t>siRNA</t> (siFAK), or siFAK for 48 hr. Bottom: protein knockdown efficiency. ∗ p < 0.05. (H) Top: phase images of hESCs after knockdown with β2-microglobulin siRNA (siB2M) control or siFAK for 66 hr. Bottom: hESCs after treatment with 10 μg/mL of IgG isotype or MAB13 antibody for 24 hr. Scale bars, 100 μm (top) and 50 μm (bottom). (I) Quantification of Annexin V-positive hESCs after knockdown with siB2M or siFAK (66 hr). ∗∗ p < 0.03. (J) Quantification of Annexin V/7-AAD-positive hESCs after knockdown with siB2M or siFAK (66 hr). (K) Quantification of Annexin V/7-AAD-positive hESCs treated with IgG or MAB13 antibody (24 hr). ∗ p < 0.05. Data represent mean + SEM (n = 3 experiments). See also <xref ref-type=Figure S2 . " width="250" height="auto" />
    Target Specific Fak Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/target specific fak sirna/product/Santa Cruz Biotechnology
    Average 91 stars, based on 1 article reviews
    target specific fak sirna - by Bioz Stars, 2026-02
    91/100 stars
    		  Buy from Supplier

    Image Search Results


    Inhibition of FAK Signaling Induces Cell Blebbing and a Caspase-Dependent Anoikis (A) Quantification of Annexin V/7-AAD positive cells by flow cytometry in hESCs treated for 24 hr with the indicated concentrations of PF562271, DMSO, or untreated. ∗ p < 0.05 relative to DMSO. (B) Caspase activity in hESCs treated for 5 hr with the indicated concentration of FAK inhibitors. ∗ p < 0.05 relative to DMSO. (C) Caspase activity in hESCs treated for 5 hr with the indicated concentration of AKT inhibitors. ∗ p < 0.05 relative to DMSO. (D) Cleaved caspase-3 expression in hESCs treated with DMSO, FAKi only, or with 50 μM ZVAD-FMK for 24 hr. ∗ p < 0.05 relative to DMSO. (E) Phase images of hESCs treated for 24 hr with DMSO, FAKi only, or with Z-VAD-FMK. Inset shows blebbing in a single cell (a) or groups of cells (b). Scale bar, 100 μm. (F) Dot plots of Annexin V/7-AAD-positive cells in hESCs treated for 24 hr with DMSO, FAKi only, or with Z-VAD-FMK. (G) Immunoblot for FAK and GAPDH in hESCs nucleofected with mock control, control GFP vector (ctl vector) plus FAK siRNA (siFAK), or siFAK for 48 hr. Bottom: protein knockdown efficiency. ∗ p < 0.05. (H) Top: phase images of hESCs after knockdown with β2-microglobulin siRNA (siB2M) control or siFAK for 66 hr. Bottom: hESCs after treatment with 10 μg/mL of IgG isotype or MAB13 antibody for 24 hr. Scale bars, 100 μm (top) and 50 μm (bottom). (I) Quantification of Annexin V-positive hESCs after knockdown with siB2M or siFAK (66 hr). ∗∗ p < 0.03. (J) Quantification of Annexin V/7-AAD-positive hESCs after knockdown with siB2M or siFAK (66 hr). (K) Quantification of Annexin V/7-AAD-positive hESCs treated with IgG or MAB13 antibody (24 hr). ∗ p < 0.05. Data represent mean + SEM (n = 3 experiments). See also <xref ref-type=Figure S2 . " width="100%" height="100%">

    Journal: Stem Cell Reports

    Article Title: Integrin-Associated Focal Adhesion Kinase Protects Human Embryonic Stem Cells from Apoptosis, Detachment, and Differentiation

    doi: 10.1016/j.stemcr.2016.07.006

    Figure Lengend Snippet: Inhibition of FAK Signaling Induces Cell Blebbing and a Caspase-Dependent Anoikis (A) Quantification of Annexin V/7-AAD positive cells by flow cytometry in hESCs treated for 24 hr with the indicated concentrations of PF562271, DMSO, or untreated. ∗ p < 0.05 relative to DMSO. (B) Caspase activity in hESCs treated for 5 hr with the indicated concentration of FAK inhibitors. ∗ p < 0.05 relative to DMSO. (C) Caspase activity in hESCs treated for 5 hr with the indicated concentration of AKT inhibitors. ∗ p < 0.05 relative to DMSO. (D) Cleaved caspase-3 expression in hESCs treated with DMSO, FAKi only, or with 50 μM ZVAD-FMK for 24 hr. ∗ p < 0.05 relative to DMSO. (E) Phase images of hESCs treated for 24 hr with DMSO, FAKi only, or with Z-VAD-FMK. Inset shows blebbing in a single cell (a) or groups of cells (b). Scale bar, 100 μm. (F) Dot plots of Annexin V/7-AAD-positive cells in hESCs treated for 24 hr with DMSO, FAKi only, or with Z-VAD-FMK. (G) Immunoblot for FAK and GAPDH in hESCs nucleofected with mock control, control GFP vector (ctl vector) plus FAK siRNA (siFAK), or siFAK for 48 hr. Bottom: protein knockdown efficiency. ∗ p < 0.05. (H) Top: phase images of hESCs after knockdown with β2-microglobulin siRNA (siB2M) control or siFAK for 66 hr. Bottom: hESCs after treatment with 10 μg/mL of IgG isotype or MAB13 antibody for 24 hr. Scale bars, 100 μm (top) and 50 μm (bottom). (I) Quantification of Annexin V-positive hESCs after knockdown with siB2M or siFAK (66 hr). ∗∗ p < 0.03. (J) Quantification of Annexin V/7-AAD-positive hESCs after knockdown with siB2M or siFAK (66 hr). (K) Quantification of Annexin V/7-AAD-positive hESCs treated with IgG or MAB13 antibody (24 hr). ∗ p < 0.05. Data represent mean + SEM (n = 3 experiments). See also Figure S2 .

    Article Snippet: hESCs were treated with 10 μM Y27632 (Sigma-Aldrich) for 1 hr and nucleofected with Amaxa Nucleofector following the manufacturer's instructions (Lonza), with target-specific FAK siRNA (sc-29310, Santa Cruz Biotechnology) at a final concentration of 200 nM, β-2-microglobulin siRNA control (Life Technologies), or pmaxGFP control vector (Lonza).

    Techniques: Inhibition, Flow Cytometry, Activity Assay, Concentration Assay, Expressing, Western Blot, Control, Plasmid Preparation, Knockdown